Menu

Penumbra, Inc. PEN

Full chart Compare
Set alert

Price alert · PEN

All alert types
319.21 USD -1.90 (-0.59%)

At closeNov 6, 2026, 5:49 PM EST

319.00 -0.21 -0.07%

After hours · Nov 6, 5:49 PM ET

319.03 Day range 320.72
264.61 52-week range 359.40
YTD
+2.67%
1 year
+20.63%
Market cap
12.58B
Revenue (ttm)
1.56B
Profit margin
10.06%
EPS (ttm)
3.97
Shares out
39.41M
P/E ratio
80.41
Forward P/E
51.83
YTD return
+2.67%
1-year return
+20.63%
Volume
336.73K
Avg volume
351.26K
Open
319.03
Previous close
321.11
Day's range
319.03 – 320.72
52-week range
264.61 – 359.40
Beta
0.69
Analysts
Hold
Price target
362.54 (+13.6%)
Earnings date
Feb 24, 2027

5D +0.24 (+0.08%)

320322324MonTueWedThuFri319.21

Key statistics

Enterprise value
12.19B
PEG ratio
3.62
Price / sales
8.07
Price / book
7.95
Dividend yield
0.00%
Payout ratio
0.00%
Revenue growth
15.60%
Free cash flow
166.09M
Total cash
673.61M
Total debt
209.39M
Return on equity
10.67%
Short % of float
6.60%
50-day average
320.28
200-day average
326.84

Financials — quick view

All financials
PEN Revenue — quarterly 410.14M
2022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 20262026-Q3 2026
PEN Net income — quarterly 42.28M
2022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 20262026-Q3 2026
PEN EPS — quarterly 1.07
2022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 20262026-Q3 2026

Earnings

PEN recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
Feb 24, 2027Dec 30, 20261.44———
Oct 29, 2026Sep 30, 20261.201.07-0.13-10.83%
Jul 30, 2026Jun 30, 20261.160.88-0.28-24.14%
May 6, 2026Mar 31, 20261.040.82-0.22-21.15%
Feb 25, 2026Dec 31, 20251.111.18+0.07+6.31%
Nov 5, 2025Sep 30, 20250.9290.97+0.04+4.41%

Upgrades / downgrades

PEN analyst upgrades and downgrades
DateFirmActionFromTo
Jul 6, 2026Evercore ISI GroupmainOutperformOutperform
Jun 11, 2026RBC CapitalreitSector PerformSector Perform
May 7, 2026CitigroupmainNeutralNeutral
May 7, 2026Evercore ISI GroupmainOutperformOutperform
Feb 26, 2026Evercore ISI GroupmainOutperformOutperform
Jan 20, 2026RBC CapitaldownOutperformSector Perform

About Penumbra, Inc.

Penumbra, Inc., together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. It offers computer-assisted vacuum thrombectomy; peripheral thrombectomy products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX. It also provides access products, including guide catheters and the Penumbra distal delivery catheters under the Neuron, Neuron MAX, BENCHMARK, BMX, DDC, Access25; MIDWAY, and PX SLIM brands; Penumbra System, an integrated mechanical thrombectomy system comprising reperfusion catheters and separators, the 3D Revascularization device, aspiration tubing, aspiration pump, and other components and accessories under the Penumbra RED, SENDit, JET, ACE, BMX, Max, 3D Revascularization Device, and Penumbra ENGINE brands; and neuro embolization coiling systems that include the Penumbra Coil 400, for the treatment of aneurysms and other complex lesions, detachable coils of neurovascular lesions under the Penumbra SMART COIL, SwiftSET, and Penumbra SwiftPAC Coil brands; and POD400 and PAC400 brands. In addition, it provides peripheral embolization products, such as Ruby Embolization Platform, which consists of detachable coils for peripheral applications; Ruby LP and XL Embolization Platform; Penumbra LANTERN Delivery Microcatheter, a low-profile microcatheter with a high-flow lumen; POD (Penumbra Occlusion Device) System, a single device solution; Packing Coil LP; and Packing Coil, a complementary device for use in other peripheral embolization products. Further, it offers neurosurgical tools comprising the Artemis Neuro Evacuation Device for surgical removal of fluid and tissue from the ventricles and cerebrum. It sells its products through direct sales organizations and distributors. The company was incorporated in 2004 and is based in Alameda, California.

Sector
Healthcare
Industry
Medical Devices
Country
United States

News

Your note

Sign in to keep a note on PEN — it syncs with the Stock Master app.

Insider holders

PEN insider holders
InsiderRelationLatest transactionDateShares held
BOSE ARANIDirectorStock Award(Grant)Feb 12, 2026259,609
ELSESSER ADAMChief Executive OfficerStock GiftMay 18, 20260
GREWAL HARPREET SINGHDirectorSaleApr 1, 20268,719
KASSING DON WDirectorStock Award(Grant)Feb 13, 20259,909
LEEDS JANETDirectorStock Award(Grant)Feb 12, 20266,639
NARAYAN SHRUTHIPresidentStock Award(Grant)Aug 16, 202633,880

Institution ownership

PEN institution ownership
Holder% heldSharesValueReported
Blackrock Inc.10.90%4,297,5551.37BJun 29, 2026
HBK Investments L P4.66%1,838,508587.08MJun 29, 2026
Vanguard Capital Management LLC4.34%1,709,877546.01MJun 29, 2026
Vanguard Portfolio Management LLC4.23%1,667,276532.40MJun 29, 2026
State Street Corporation3.15%1,243,258397.00MJun 29, 2026
ExodusPoint Capital Management, LP2.77%1,090,430348.20MJun 29, 2026

Fund ownership

PEN fund ownership
Holder% heldSharesValueReported
iShares Trust-iShares Core S&P Mid-Cap ETF3.56%1,403,042448.03MSep 29, 2026
VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund3.01%1,186,100378.75MJun 29, 2026
VANGUARD INDEX FUNDS-Vanguard Small-Cap Index Fund2.17%856,690273.56MJun 29, 2026
VANGUARD INDEX FUNDS-Vanguard Small-Cap Growth Index Fund1.25%494,387157.87MJun 29, 2026
VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund1.14%450,774143.94MJun 29, 2026
SmallCap World Fund Inc1.05%412,644131.77MSep 29, 2026